Phase 3 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to give written, signed, and dated consent to take part in the study.
• People who have been confirmed through laboratory testing to have triple negative breast cancer.
• People who have received no more than one chemotherapy treatment after surgery and/or one chemotherapy treatment for cancer that has spread.
• People whose breast cancer has spread locally or to other parts of the body and has stopped responding to prior chemotherapy.
• People who have at least one tumour that can be measured using standard imaging criteria (confirm with trial site).
• People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (confirm with trial site).
• People whose heart pumping function, measured by an ultrasound of the heart, is at or above 50%.
• People who have recovered from any side effects of previous chemotherapy or radiation, as assessed by the study doctor.
• People who completed their last chemotherapy or radiation treatment at least 4 weeks before the start of the trial treatment.
• People who are expected to live for at least 6 months.
• People whose pregnancy tests (blood test at screening and urine test on Day 1) are negative.
• Women who are sexually active and able to become pregnant must be using an effective form of contraception for at least 4 weeks before starting the trial, throughout the trial, and for 30 days after the last dose (confirm with trial site for accepted contraception methods).
• People with adequate bone marrow, kidney, and liver function as determined by blood tests.

Who may not be able to join:

• People who have had an allergic reaction to Docetaxel, any of its ingredients, or any medicine containing polysorbate 80.
• People who have a history of a breast cancer type that is HER2 positive or hormone receptor positive (ER or PR positive).
• People who have already received Docetaxel treatment for cancer that has spread to other parts of the body.
• People with certain heart conditions, including unstable chest pain, a heart attack in the past 6 months, severe uncontrolled irregular heartbeat, significant disease around the heart, signs of reduced blood supply to the heart on an ECG, or a history of heart disease rated at a moderate-to-severe level by a standard medical classification (confirm with trial site).
• People with uncontrolled diabetes or an active uncontrolled infection.
• People with a known history of drug addiction within the past year.
• People with known cancer spread to the brain or the lining of the brain, unless those brain lesions are not causing any symptoms.
• People who have taken part in another clinical trial or received an experimental medicine within 30 days before starting this trial.
• People who already have nerve damage (affecting movement or sensation) at or above a certain level of severity before the trial begins (confirm with trial site).
• People with a known HIV infection.
• People with any other condition that the study doctor believes could increase risk or affect the quality of the study results.
• People who are unwilling or unable to follow the requirements of the study.

Important: Always verify eligibility with the trial site directly before applying.